Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomes

This publication has 25 references indexed in Scilit:

• Variable contribution of CYP2D6 to the N‐Dealkylation of S‐(‐)‐propranolol by human liver microsomes
  British Journal of Clinical Pharmacology, 1996
• Evidence That Aspartic Acid 301 Is a Critical Substrate-Contact Residue in the Active Site of Cytochrome P450 2D6
  Published by Elsevier ,1995
• Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer
  Annual Review of Pharmacology and Toxicology, 1995
• Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
  Xenobiotica, 1995
• Genotoxicity of tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s
  Carcinogenesis: Integrative Cancer Research, 1994
• A Risk-Benefit Assessment of Tamoxifen Therapy
  Drug Safety, 1993
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
  Chemical Research in Toxicology, 1992
• Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
  Chemical Research in Toxicology, 1991
• Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1
  Chemical Research in Toxicology, 1990
• Life threatening interaction between tamoxifen and warfarin.
  BMJ, 1989